Imprimis Pharmaceuticals Inc (IMMY):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9776)
◆英語タイトル:Imprimis Pharmaceuticals Inc (IMMY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9776
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Imprimis Pharmaceuticals Inc (Imprimis), formerly Transdel Pharmaceuticals Inc., focuses on the development and commercialization of proprietary drug formulations in the therapeutic areas of urology and ophthalmology. The company by utilizing its SSP Technology develops injectable Dropless Therapy formulations and topical LessDrops formulations. Its Dropless Therapy formulations include injectable Tri-Moxi and Tri-Moxi-Vanc formulations that eliminate the need for eye drops following ocular surgery; and LessDrops include topical eye drop formulations Pred-Moxi and Tri-Moxi for patients following LASIK, cataract, and other ocular surgeries. Imprimis also commercializes heparin and alkalinized lidocaine (Hep-Lido-A or HLA) formulations for the treatment of interstitial cystitis; and injectable pentoxifylline formulation for the treatment of peyronie’s disease. The company markets its products through distributors and compounding pharmacies. Imprimis is headquartered in San Diego, California, the US.

Imprimis Pharmaceuticals Inc (IMMY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Imprimis Pharma Acquires Rights to Proprietary Sedation Formulations from Vance Thompson Vision 13
Imprimis Pharma Acquires Intellectual Property For Ophthalmic Compound Development 14
Imprimis Pharma Acquires Intellectual Property Assets From Buderer Drug Company 15
Licensing Agreements 16
Eton Pharma Receives Rights of CT-100 from Imprimis Pharma 16
Imprimis Pharma Enters into Licensing Agreement with Richard L. Lindstrom 17
Imprimis Pharma Enters into License Agreement with Urigen Pharma 18
Imprimis Pharmaceuticals Enters into Licensing Agreement with Advanced Dosage Forms 20
Imprimis Pharma Enters Into Licensing Agreement With ResolutionMD For Cosmeceutical Products 21
Equity Offering 22
Imprimis Pharma Raises USD0.2 Million in Private Placement of Shares, upon Exercise of Warrants 22
Imprimis Pharma Raises USD3 Million in Private Placement of Shares 23
Imprimis Pharma Files Registration Statement for Public Offering of Shares 24
Imprimis Pharma to Raise USD10 Million in Private Placement of Units 25
Imprimis Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD12 Million 26
Imprimis Pharma to Raise up to USD10 Million in Public Offering of Shares 28
Imprimis Pharma Completes Underwriters’ Exercise Of Over-Allotment Option For US$11.1 Million 29
Imprimis Pharma Completes Private Placement Of Units For US$8 Million 30
Debt Offering 31
Imprimis Pharma Raises USD3 Million in Private Placement of 8% Note Due 2021 31
Asset Transactions 32
Imprimis Pharma Sells Pennsylvania Facility and Sinus Assets 32
Acquisition 33
Imprimis Pharmaceuticals Acquires JT Pharmacy for USD0.42 Million 33
Imprimis Pharma Acquires South Coast Specialty Compounding 34
Professional Compounding Centers of America Acquires Minority Stake In Imprimis Pharma For US$4 Million 35
Imprimis Pharmaceuticals Inc – Key Competitors 36
Imprimis Pharmaceuticals Inc – Key Employees 37
Imprimis Pharmaceuticals Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 40
Strategy And Business Planning 40
Oct 24, 2017: Imprimis Launches Surface Pharmaceuticals Subsidiary 40
Financial Announcements 41
Aug 06, 2018: Imprimis Pharmaceuticals announces second quarter 2018 results 41
May 15, 2018: Imprimis Pharmaceuticals Announces First Quarter 2018 Results 42
Mar 08, 2018: Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results 43
Nov 14, 2017: Imprimis Pharmaceuticals Announces Third Quarter 2017 Results 44
Aug 10, 2017: Imprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results 46
May 10, 2017: Imprimis Pharmaceuticals Announces First Quarter 2017 Financial Results 47
Mar 21, 2017: Imprimis Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results 48
Legal and Regulatory 50
Jan 24, 2018: Imprimis Pharmaceuticals Receives DEA Manufacturer Controlled Substance Registration Certificate 50
Sep 14, 2017: FDA Curcumin Investigation Supports Imprimis Statement 51
Sep 11, 2017: Imprimis Releases Statement Regarding Allergan Lawsuit 52
Sep 07, 2017: Allergan Files Suits Against Imprimis Pharmaceuticals Prescriber’s Choice and Sincerus Florida 53
Product News 54
Oct 19, 2017: Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis 54
Other Significant Developments 55
Mar 06, 2018: Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations 55
Jul 20, 2017: Imprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings 56
Feb 16, 2017: Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Imprimis Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Imprimis Pharma Acquires Rights to Proprietary Sedation Formulations from Vance Thompson Vision 13
Imprimis Pharma Acquires Intellectual Property For Ophthalmic Compound Development 14
Imprimis Pharma Acquires Intellectual Property Assets From Buderer Drug Company 15
Eton Pharma Receives Rights of CT-100 from Imprimis Pharma 16
Imprimis Pharma Enters into Licensing Agreement with Richard L. Lindstrom 17
Imprimis Pharma Enters into License Agreement with Urigen Pharma 18
Imprimis Pharmaceuticals Enters into Licensing Agreement with Advanced Dosage Forms 20
Imprimis Pharma Enters Into Licensing Agreement With ResolutionMD For Cosmeceutical Products 21
Imprimis Pharma Raises USD0.2 Million in Private Placement of Shares, upon Exercise of Warrants 22
Imprimis Pharma Raises USD3 Million in Private Placement of Shares 23
Imprimis Pharma Files Registration Statement for Public Offering of Shares 24
Imprimis Pharma to Raise USD10 Million in Private Placement of Units 25
Imprimis Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering for USD12 Million 26
Imprimis Pharma to Raise up to USD10 Million in Public Offering of Shares 28
Imprimis Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$11.1 Million 29
Imprimis Pharma Completes Private Placement Of Units For US$8 Million 30
Imprimis Pharma Raises USD3 Million in Private Placement of 8% Note Due 2021 31
Imprimis Pharma Sells Pennsylvania Facility and Sinus Assets 32
Imprimis Pharmaceuticals Acquires JT Pharmacy for USD0.42 Million 33
Imprimis Pharma Acquires South Coast Specialty Compounding 34
Professional Compounding Centers of America Acquires Minority Stake In Imprimis Pharma For US$4 Million 35
Imprimis Pharmaceuticals Inc, Key Competitors 36
Imprimis Pharmaceuticals Inc, Key Employees 37
Imprimis Pharmaceuticals Inc, Subsidiaries 38

List of Figures
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Imprimis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Imprimis Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Imprimis Pharmaceuticals Inc (IMMY):製薬・医療:M&Aディール及び事業提携情報(Imprimis Pharmaceuticals Inc (IMMY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆